Recro Pharma (REPH) PT Raised to $14 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts REPH Hot Sheet
Price: $2.09 --0%
Rating Summary:
10 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
10 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Piper Jaffray analyst David Amsellem raised the price target on Recro Pharma (NASDAQ: REPH) to $14.00 (from $11.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applied Industrial Technologies (AIT) PT Lowered to $360 at KeyBanc
- Travel + Leisure (TNL) PT Raised to $91 at Stifel
- JPMorgan Assumes Airtac International (1590:TT) at Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
